A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

NCT04255862 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
71
Enrollment
INDUSTRY
Sponsor class

Stopped Study recruitment temporarily halted due to difficulties executing the study under the COVID-19 pandemic

Conditions

Interventions

Sponsor

UCB Biopharma SRL